Start here
Guides across all compounds
PeptideHound documents what published research reports for 49 peptide research compounds: what was studied, in what model, at what amounts, and what remains unknown.1
Enter what is on your vial and the diluent you added. Arithmetic only; it never suggests an amount.
mg × 1000 ÷ mL = mcg/mL
mcg ÷ (mcg/mL) = mL · mL × 100 = units
Side effects and interactions, with the evidence behind each.
All 49 safety pages →203 sellers on record, 68 fully checked. Never a ranking.
What each record checks →49 compounds1,529 citations linked203 vendor recordsUpdated How we source
Every page below states what the research found, labels the kind of study it came from, and says plainly what has not been studied.
The benefits measured for Cerebrolysin are gains on recovery scales in hospital patients: arm movement and speech after stroke, memory and global function in dementia, and coma and outcome scores after brain injury. Most were seen in the first weeks, and the longer-term and survival outcomes are weaker or absent.
Cerebrolysin trials measured it in millilitres of solution dripped into a vein, most often 30 mL a day for 10 to 21 days after stroke and 30 mL five days a week for four weeks in Alzheimer's disease. Those are amounts that hospital trial teams chose for patients with a diagnosis, reported here as study parameters.
Cerebrolysin is a peptide preparation made from pig brain and given by infusion into a vein, used in hospitals in dozens of countries for stroke, brain injury and dementia. Its trial record is large, and the reviews of that record disagree about whether it helps.
Every measured benefit of LL-37 comes from cells and animals: it improved wound repair in mice, calmed eye inflammation in rats and limited bacterial invasion of mouse tissue. None of the studies behind this page gave it to a person, so a human benefit has yet to be measured.
Semaglutide is a once-weekly injection that copies a gut hormone the body releases after a meal, and the human evidence behind it is unusually large and the approval is real. A 2023 review records that it was recently approved by the US Food and Drug Administration for chronic weight management.
C-peptide is not something anybody takes: it is a short piece of protein the pancreas cuts loose every time it makes insulin, and people search for it because of a line on a laboratory report. It is released one piece for every molecule of insulin, which is what makes the reading a count of what the pancreas is making.
Larazotide (larazotide acetate, AT-1001) has measured benefits in one setting: symptom scores in adults with coeliac disease, most clearly when they were deliberately given gluten. The urine test of gut leakiness it was designed to improve did not differ from placebo in the pooled trials.
Larazotide (larazotide acetate, also coded AT-1001) is an oral research compound built to tighten the seals between gut cells, tested mainly as an add-on to the gluten-free diet in coeliac disease. Across four randomised trials the picture was mixed: some symptom scores improved, while the gut permeability test it was designed to change did not.
BAM15 is a research compound that makes mitochondria burn fuel less efficiently, and the short version is that the mouse record is consistent while the human record, among the sources behind this page, has not started. It is a synthetic small molecule rather than a peptide, though it is sold and searched as one.
BAM15 has no human harm record among the sources behind this page, and what stands in its place is a set of mouse experiments that were measuring something else. That distinction is the whole page: an adverse effect nobody looked for is not an adverse effect nobody found.
Cerebrolysin's harm record comes from placebo-controlled trials in stroke and dementia patients, which is more than most research compounds have. The reviews of those trials disagree: Cochrane found a possible rise in non-fatal serious adverse events, while other meta-analyses found no difference from placebo.
Argireline (acetyl hexapeptide-8, also sold as acetyl hexapeptide-3) is a cosmetic peptide designed to copy the wrinkle-relaxing action of Botox from a cream rather than a needle. Whether it reaches the muscles it was designed for is unsettled, and the human trials behind it are small and a few weeks long.
The gaps in the evidence matter as much as the findings.
Status is a regulatory fact, not a rating.
Hormone made in nerves — human data is mostly measured levels and single research infusions
Mitochondria-targeted; studied mainly in rare mitochondrial disease
Daily GLP-1 drug approved for type 2 diabetes and weight management
Pregnancy hormone with a fertility-care trial record — no weight-loss trial behind the page
Marker of the pancreas's own insulin output — measured, not taken
Approved for low sexual desire in premenopausal women
For a reader who has not picked a compound yet — what these are, how they are used, and how they compare.
Arithmetic, shown step by step. None of these tools suggests an amount to use.
Twelve-month change in search interest. A rising line means more people are looking, not that a compound works.
203 sellers on record; 68 have a completed record so far, checked against business registries, FDA enforcement and domain history. The rest are listed with no finding yet. Never a rating or a ranking.
A peptide is a short chain of amino acids — the same building blocks as a protein, just fewer of them. The body makes thousands of them, and they act as signals: telling a cell to release a hormone, to repair, to take in fuel.
That signalling is why they draw interest, and it is also why the category is so uneven. A few are approved drugs with large trials behind them. Most of the compounds people search for have been studied only in animals or cells, and some have never been given to a person at all. We label which is which on every page, because the difference is the whole story.
Cited, or not written
Every claim carries the sentence from the source that supports it, checked character-for-character before the page can publish.
Evidence, labelled
Each claim shows the kind of study behind it — human trial, animal model, cell work — so you can weigh it yourself.
What we don't know
Every compound page says plainly what has not been studied. The gaps matter as much as the findings.
Pages are re-checked against their sources on a rolling basis. The date is when a person last read the page against the papers behind it.